Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) saw unusually-high trading volume on Thursday. 328,839 shares were traded during mid-day trading, an increase of 34% from the previous session’s volume of 246,080 shares. The stock last traded at $19.0580 and had previously closed at $19.31.
Wall Street Analysts Forecast Growth
CHGCY has been the subject of a number of recent research reports. The Goldman Sachs Group upgraded Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research note on Tuesday, September 1st. Finally, UBS Group downgraded shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy”.
Check Out Our Latest Stock Report on Chugai Pharmaceutical
Chugai Pharmaceutical Stock Performance
Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last released its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. The business had revenue of $2.14 billion during the quarter, compared to analyst estimates of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%. Research analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 EPS for the current fiscal year.
Chugai Pharmaceutical Company Profile
Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization.
Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer.
Further Reading
- Five stocks we like better than Chugai Pharmaceutical
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
